FDA-Approved Marijuana Products Move to Schedule III
The U.S. Department of Justice has rescheduled FDA-approved marijuana drug products from Schedule I to Schedule III under the Controlled Substances Act, effective April 28, 2026. This change applies to marijuana, marijuana extracts, and delta-9-tetrahydrocannabinol derived from the marijuana plant (excluding mature stalks and seeds) when included in FDA-approved drugs or subject to state medical marijuana licenses. Import and export of these products now require federal permits, and entities holding state medical marijuana licenses can register expeditiously under 21 CFR part 1301 to legally manufacture, distribute, and dispense marijuana for medical purposes under federal law.
Photo: Elsa Olofsson / Pexels# FDA-Approved Marijuana Products Rescheduled to Schedule III
Effective April 28, 2026, the Acting Attorney General of the U.S. Department of Justice has issued a final rule moving FDA-approved drug products containing marijuana from Schedule I to Schedule III of the Controlled Substances Act. This rescheduling fulfills U.S. obligations under the Single Convention on Narcotic Drugs, 1961.
What's Covered
The rule applies to marijuana as defined in the CSA, marijuana extracts, and delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant—excluding mature stalks and seeds—when:
- Included in an FDA-approved drug product, or
- Subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or marijuana products for medical purposes
"This action is required to satisfy the responsibility of the Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961."
— Federal Register, April 28, 2026
Import/Export Permit Requirements
Schedule III placement adds these substances to the list of controlled materials requiring federal permits for import and export. Shippers and distributors must obtain permits before moving FDA-approved marijuana products across borders.
Expedited Registration for State-Licensed Entities
The rule establishes an expedited registration process under 21 CFR part 1301, allowing entities holding state medical marijuana licenses to:
- Manufacture marijuana for medical purposes
- Distribute marijuana products
- Dispense marijuana under federal law
This streamlined registration enables state-licensed operators to comply with both state and federal requirements simultaneously.
What this means for shippers
If you handle pharmaceutical shipments or medical products containing marijuana, you now must verify federal permit status before moving goods internationally. Schedule III classification impacts duty treatment, permit costs, and compliance documentation. Review our sanctions resource for current restricted-party screening requirements and permit procedures.
